Skip to main content

Day: November 4, 2024

Whitestone REIT Continues Board Refreshment with Appointment of Two Independent Trustees

Written by Customer Service on . Posted in Public Companies.

Veteran Real Estate C-Suite Executives Kristian M. Gathright and Donald A. Miller Bring Deep Industry Expertise and Financial and Operational Acumen HOUSTON, Nov. 04, 2024 (GLOBE NEWSWIRE) — Whitestone REIT (NYSE: WSR) (“Whitestone” or the “Company”) today announced the appointments of Kristian (“Krissy”) M. Gathright and Donald (“Don”) A. Miller, CFA, to the Board of Trustees, effective immediately. These appointments reflect shareholder feedback received over the last several months and conclude an exhaustive search by Whitestone’s Nominating and Governance Committee in combination with pre-eminent executive search firm Spencer Stuart. Ms. Gathright currently serves as a Board member of Apple Hospitality REIT (NYSE: APLE) that owns one of the largest and most diverse portfolios of upscale, rooms-focused hotels in the United States....

Continue reading

AMG Reports Financial and Operating Results for the Third Quarter and Nine Months Ended September 30, 2024

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Company reports EPS of $3.78, Economic EPS of $4.82 in the third quarter of 2024Net income (controlling interest) of $124 million, Economic Net Income (controlling interest) of $153 million Economic Earnings per share of $4.82 for the quarter, increased 18% year-over-year Repurchased $103 million in common stock, bringing year-to-date share repurchases to $580 millionWEST PALM BEACH, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, today reported its financial and operating results for the third quarter and nine months ended September 30, 2024. Jay C. Horgen, President and Chief Executive Officer of AMG, said:“AMG delivered strong results in the third quarter, including year-over-year growth of 18% in Economic Earnings per share, reflecting the ongoing...

Continue reading

TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 – $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ET    NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with recent company developments and provided an update on 2024 revenue guidance. Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are excited to share with you the results of another quarter of growth and execution of our BRIUMVI launch and pipeline development. With $83.3 million of U.S. BRIUMVI net...

Continue reading

BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company introduces full-year 2024 total product revenue guidance of $443-$448 million based on additional 2024 revenue from RAPIVAB — — BCX17725 for Netherton syndrome advances into the clinic — — Company generates GAAP operating profit of $7.7 million in third quarter ($24.9 million non-GAAP operating profit) — RESEARCH TRIANGLE PARK, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “Our third quarter performance continues to build on the outstanding year we are having, with significant revenue growth,...

Continue reading

FTI Consulting Expands Financial Services Practice with Appointment of Two Senior Managing Directors

Written by Customer Service on . Posted in Public Companies.

WASHINGTON, Nov. 04, 2024 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Caitlin Holmes and Mark Sexton as Senior Managing Directors in the Financial Services practice within the firm’s Forensic and Litigation Consulting segment, further enhancing the firm’s risk management and regulatory compliance services. “Financial services organizations are experiencing an immense shift in the status quo, leading to a heightened risk landscape, whether it’s related to new regulations, technological advancements or competition in the industry,” said Stella Mendes, Leader of the Financial Services practice at FTI Consulting. “Caitlin and Mark bring deep knowledge of the regulatory and compliance space and can address the individual challenges our clients face in order to implement tailored solutions....

Continue reading

Aveanna Healthcare Holdings Announces Appointment of New Director

Written by Customer Service on . Posted in Public Companies.

ATLANTA, Nov. 04, 2024 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Brent Layton to serve as a Class III director of the Board of Directors of Aveanna Healthcare Holdings Inc., and additionally as a member of the Audit Committee of the Board, effective November 1, 2024. “I am delighted to announce the appointment of Brent Layton to our Aveanna Board of Directors. Brent brings a wealth of healthcare knowledge from over 20 years of leadership at Centene Corporation. Brent’s experience working with state and federal healthcare policy makers and managed care organizations will be invaluable as we continue to grow and execute our strategic plans. Brent will...

Continue reading

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine’s proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI and the retained portions of the payments payable under the license agreement with Vertex, to fund operating expenses and capital expenditures into the...

Continue reading

SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

EDEN PRAIRIE, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) — SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, will host a live conference call on Friday, November 8, 2024, at 8:30 AM (ET) to present its Q3 2024 financial results. Telephone access to the call will be available by dialing the following numbers: Participant Dial-in Information Toll Free: 1-800-267-6316 Toll/International: 1-203-518-9783 Conference ID: SANUWAVE OR click the link for instant telephone access to the event:https://viavid.webcasts.com/starthere.jsp?ei=1692398&tp_key=e3cff43c54 Materials for the conference call will be included on the Company’s website at www.sanuwave.com/investors. A replay will be made available through November 29, 2024: Toll-Free:...

Continue reading

Form 8.3 – [ECKOH PLC – 01 11 2024] – (CGWL)

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree ECKOH PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

Freshpet, Inc. Reports Third Quarter 2024 Financial Results

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

25th Consecutive Quarter of >25% Year on Year Net Sales Growth Strong Operating Performance Drove Significant Margin Expansion & Cash Generation Company Raises 2024 Net Sales and Adjusted EBITDA Guidance BEDMINSTER, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (Nasdaq: FRPT) today reported financial results for its third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Compared to Prior Year PeriodNet sales of $253.4 million, an increase of 26.3%. Net income of $11.9 million, compared to the prior year period net loss of $7.2 million. Gross margin of 40.4%, compared to the prior year period of 33.0%. Adjusted Gross Margin of 46.5%, compared to the prior year period of 40.2%.1 Adjusted EBITDA of $43.5 million, compared to the prior year period of $23.2 million.1 For...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.